The Grifols logo at its headquarters in Sant Cugat del Vallès, near Barcelona, ​​Spain, on May 25, 2018. . / Albert Gea (Albert Gea /)

Jul 28 (.) – Grifols blood product group announced Tuesday that it delivered the first batches of its hyperimmune immunoglobulin to treat SARS-COV-2 infection for use in clinical trials.

Grifols said, in a press release, that the drug was developed to provide passive immunization for patients and that it could be used in both prevention and treatment of the disease.

Anti-SARS-CoV-2 hyperimmune immunoglobulin is produced from the « plasma of healthy donors who have recovered from COVID-19, (…) which has a high and consistent concentration of protective antibodies against the new coronavirus « Grifols said.

The group reached an agreement with the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the Advanced Biomedical Research and Development Authority (BARDA) for the development of preclinical and clinical studies necessary to determine the efficacy of the therapy.

(Information from Michael Susin; Edited by Emma Pinedo)